This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Warren, A. J. Articles by Hamilton, J. W. Search for Related Content PubMed PubMed Citation Articles by Warren, A. J. Articles by Hamilton, J. W.

Detection of Mitomycin C-DNA Adducts in Human Breast Cancer Cells Grown in Culture, as Xenografted Tumors in Nude Mice, and in Biopsies of Human Breast Cancer Patient Tumors as Determined by ³²P-Postlabeling¹

Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755-3835 [A. J. W., D. J. M., J. W. H.], and Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756-0001 [J. W. H.]

Mitomycin C (MMC) is a DNA cross-linking agent that has been used in cancer chemotherapy for >20 years. However, little is known either qualitatively or quantitatively about the relationship between formation and repair of specific MMC-DNA adducts and specific biological outcomes. The goal of this study was to examine formation and removal of specific MMC-DNA adducts in breast cancer cells using a ³²P-postlabeling assay in relation to cytotoxicity and other biological end points. MMC-DNA adducts were measured in cultured human metastatic MDA-MB-435 cells, in the same cells xenografted as a mammary tumor in nude mice, and in metastatic tumor biopsies obtained from human breast cancer patients undergoing MMC-based therapy. MMC adducts corresponding to the CpG interstrand cross-link, the MMC-G bifunctional monoadduct, and two isomers of the MMC-G monofunctional monoadduct were detected in most samples. Despite similarities in the overall patterns of adduct formation, there were substantial differences between the cultured cells and the in vivo tumors in their adduct distribution profile, kinetics of adduct formation and removal, and relationship of specific adduct levels to cytotoxicity, suggesting that the in vivo microenvironment (e.g., degree of oxygenation, pH, activity of oxidoreductases, and other factors) of breast cancer cells may significantly modulate these parameters.

This article has been cited by other articles:

				L. J. Niedernhofer, H. Odijk, M. Budzowska, E. van Drunen, A. Maas, A. F. Theil, J. de Wit, N. G. J. Jaspers, H. B. Beverloo, J. H. J. Hoeijmakers, et al. The Structure-Specific Endonuclease Ercc1-Xpf Is Required To Resolve DNA Interstrand Cross-Link-Induced Double-Strand Breaks Mol. Cell. Biol., July 1, 2004; 24(13): 5776 - 5787. [Abstract] [Full Text] [PDF]

				S. Geisler, A.-L. Borresen-Dale, H. Johnsen, T. Aas, J. Geisler, L. A. Akslen, G. Anker, and P. E. Lonning TP53 Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer Clin. Cancer Res., November 15, 2003; 9(15): 5582 - 5588. [Abstract] [Full Text] [PDF]

				T. Abbas, M. Olivier, J. Lopez, S. Houser, G. Xiao, G. S. Kumar, M. Tomasz, and J. Bargonetti Differential Activation of p53 by the Various Adducts of Mitomycin C J. Biol. Chem., October 18, 2002; 277(43): 40513 - 40519. [Abstract] [Full Text] [PDF]